Improving Management of Secondary Hyperparathyroidism (SHPT) in Non-Dialysis Patients

CKD Is a Global Burden With Major Implications

CKD-MBD

Pathophysiology of CKD-MBD

Biochemical Phenotype of Disordered Mineral Metabolism in CKD

SHPT Is a Component of CKD-MBD Pathophysiology

Bone-Kidney-Parathyroid Endocrinological Feedback Loop

Vitamin D Metabolism: 1,25(OH)2 D Levels Are Tightly Regulated

Low Levels Of 25(OH)D (Calcifediol) Increase the Risk of Disease Progression and Mortality in Patients With CKD

Relationship Between 25(OH)D and PTH in CKD

Vitamin D Nomenclature

Relationship Between 25(OH)D and PTH Before and After Treatment With Vitamin D and Calcium for 8 Weeks

2017 Revised KDIGO Guidelines PTH -- Vitamin D

2017 Revised KDIGO Guidelines PTH -- Vitamin D (cont)

Management of Bone Mineral Parameters Remains the Therapeutic Goal

Management of PTH and Vitamin D

Ergocalciferol Treatment in Stage 3 and 4 CKD

Improved PTH With Calcitriol in CKD Stages 3 and 4

Oral Paricalcitol in Treatment of SHPT in CKD 3 & 4

Paricalcitol vs Calcitriol in CKD-MBD

Vitamin D Receptor Activators Did Not Improve CV Outcomes but Increased Hypercalcemia Risk

Ergocalciferol vs Paricalcitol for SHPT in CKD Stages 3 and 4

Calcifediol ER Increases 25(OH)D Levels And Reduces iPTH in Patients With Non-Dialysis CKD

Calcifediol ER Increased Serum Total 25-Hydroxyvitamin D: 1-Year Results

Calcifediol ER Lowers Plasma PTH Consistently Over Time

Calcifediol ER Has an Inconsequential Impact on Serum Calcium and Phosphorus

Comparison of Vitamin D Therapies for Stage 3-4 CKD

Summary and Conclusions

Abbreviations

Abbreviations (cont)